Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies

Click to increase image sizeClick to decrease image size

Acknowledgments

Part of this manuscript was presented at the American Society of Hematology 2020 Annual meeting.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Table 1. Frequencies of analyzed clinical trials.

Additional information

Funding

Samer Al Hadidi reports salary support by National Heart, Lung, and Blood Institute grant No. 5T32HL092332-18.